Sponsored by
We have previously shared results from the Phase 1 adult trial for oral gallium maltolate in recurrent glioblastoma (GBM), and we helped fund the expanded access program. Now, researchers at the Medical College of Wisconsin have received a $2.4 million NIH grant to further investigate the treatment for aggressive pediatric brain tumors. The research will focus on establishing a more comprehensive safety profile, identifying molecular markers that predict which tumors are most sensitive to the drug, and investigating the drug together with radiation. In preliminary animal research, gallium maltolate combined with reduced-dose radiation produced survival of eight months in one rat, compared with approximately 30-70 days in previous comparison studies. All of this work builds on the encouraging but preliminary results of the adult Phase 1 GBM trial, which is now being advanced toward Phase 2. There is also a new Phase 1 trial launching soon at the Medical College of Wisconsin for relapsed or refractory pediatric high-grade glioma and atypical teratoid rhabdoid tumor (ATRT).